"Aspirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
| Descriptor ID |
D001241
|
| MeSH Number(s) |
D02.455.426.559.389.657.410.595.176
|
| Concept/Terms |
Aspirin- Aspirin
- Acetylsalicylic Acid
- Acid, Acetylsalicylic
- 2-(Acetyloxy)benzoic Acid
|
Below are MeSH descriptors whose meaning is more general than "Aspirin".
Below are MeSH descriptors whose meaning is more specific than "Aspirin".
This graph shows the total number of publications written about "Aspirin" by people in this website by year, and whether "Aspirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 0 | 1 |
| 1998 | 2 | 2 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 2 | 2 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 2 | 4 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 3 | 2 | 5 |
| 2011 | 0 | 2 | 2 |
| 2012 | 5 | 1 | 6 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 3 | 4 |
| 2015 | 5 | 2 | 7 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 2 | 2 | 4 |
| 2020 | 4 | 1 | 5 |
| 2021 | 6 | 3 | 9 |
| 2022 | 1 | 4 | 5 |
| 2023 | 1 | 9 | 10 |
| 2024 | 3 | 4 | 7 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aspirin" by people in Profiles.
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2024 Sep 01; 9(9):808-816.
-
Impact of aspirin dose according to race in secondary prevention of atherosclerotic cardiovascular disease: a secondary analysis of the ADAPTABLE randomised controlled trial. BMJ Open. 2024 Aug 07; 14(8):e078197.
-
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial. JAMA. 2024 05 28; 331(20):1714-1721.
-
Association of Antithrombotic Drug Use With Incident Intracerebral Hemorrhage Location. Neurology. 2024 Jun 25; 102(12):e209442.
-
Age and Aspirin Dosing in Secondary Prevention of Atherosclerotic Cardiovascular Disease. J Am Heart Assoc. 2024 Feb 20; 13(4):e026921.
-
Editors' Note: IV Thrombolysis vs Early Dual Antiplatelet Therapy in Patients With Mild Noncardioembolic Ischemic Stroke. Neurology. 2024 Mar 12; 102(5):e209236.
-
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease and Diabetes Mellitus: A Subgroup Analysis of the ADAPTABLE Trial. Diabetes Care. 2024 Jan 01; 47(1):81-88.
-
Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials. Neurology. 2023 Nov 27; 101(22):e2205-e2214.
-
Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial. JAMA Cardiol. 2023 11 01; 8(11):1061-1069.
-
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors. J Am Heart Assoc. 2023 10 17; 12(20):e030385.